Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Micallef

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
American Journal of Hematology|December 6, 2018
Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018Alessia Castellino, Jose S Pulido, Patrick B Johnston, et al.
Mayo Clinic Proceedings|February 13, 2004
Therapeutic options in patients with lymphoma and severe liver dysfunctionIrene M Ghobrial, Robert C Wolf, Denise L Pereira, et al.
Leukemia & Lymphoma|October 27, 2006
The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphomaIvana N M Micallef, Ellen D Remstein, Stephen M Ansell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosisLuis F Porrata, Morie A Gertz, Mark R Litzow, et al.
Leukemia & Lymphoma|August 20, 2005
The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphomaYinlee Yoong, Luis F Porrata, David J Inwards, et al.
Leukemia & Lymphoma|October 21, 2010
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status reportMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 28, 2012
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilizationIvana N M Micallef, Shirshendu Sinha, Dennis A Gastineau, et al.
Mayo Clinic Proceedings|October 3, 2008
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiativeMorie A Gertz, Stephen M Ansell, David Dingli, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
American Journal of Hematology|December 6, 2018
Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018Alessia Castellino, Jose S Pulido, Patrick B Johnston, et al.
Mayo Clinic Proceedings|February 13, 2004
Therapeutic options in patients with lymphoma and severe liver dysfunctionIrene M Ghobrial, Robert C Wolf, Denise L Pereira, et al.
Leukemia & Lymphoma|October 27, 2006
The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphomaIvana N M Micallef, Ellen D Remstein, Stephen M Ansell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosisLuis F Porrata, Morie A Gertz, Mark R Litzow, et al.
Leukemia & Lymphoma|August 20, 2005
The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphomaYinlee Yoong, Luis F Porrata, David J Inwards, et al.
Leukemia & Lymphoma|October 21, 2010
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status reportMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 28, 2012
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilizationIvana N M Micallef, Shirshendu Sinha, Dennis A Gastineau, et al.
Mayo Clinic Proceedings|October 3, 2008
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiativeMorie A Gertz, Stephen M Ansell, David Dingli, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Pageof 7